Clinical trials: Olanzapine, completed
Schizophrenia
Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
- Trial name
- NCT00077714
- Testing
- Paliperidone ER
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia.
- Trial name
- NCT05402111
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156091
- Testing
- Olanzapine, Asenapine
- Volunteers
- 260 people
- Sponsor
- Organon and Co
Schizophrenia
SB-773812 Administered In Adults With Schizophrenia
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo…
- Trial name
- NCT00259870
- Testing
- SB-773812, Olanzapine
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Bipolar I Disorder
A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
Whether treatment with olanzapine in combination with mood stabilizer reduces symptoms of both mania and depression more than treatment with mood stabilizer alone, in patients with a mixed episode of bipolar I disorder.
- Trial name
- NCT00402324
- Testing
- olanzapine, divalproex
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Phase 1 Safety Study in Adults With Schizophrenia
This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine and samidorphan in adults with schizophrenia following 14 consecutive days of oral administration of ALKS 3831.
- Trial name
- NCT02804568
- Testing
- ALKS 3831
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
Participants who have completed the 6-week trial P05688 can be screened for eligibility for this 26-week extension study in which they will continue treatment.
- Trial name
- NCT01617200
- Testing
- Asenapine, Olanzapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Forest Laboratories
Schizophrenia
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
- Trial name
- NCT02873208
- Testing
- ALKS 3831
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 266 people
- Sponsor
- Alkermes, Inc.
Fed
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
- Trial name
- NCT01503450
- Testing
- Olanzapine OD Tablets 5 mg
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Weight-Gain Prevention
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
This is a two-week study testing the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight and BMI.
- Trial name
- NCT00455442
- Testing
- Mifepristone
- Where
- India
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizophrenia
Phase IIA Study in Patients With Schizophrenia
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
- Trial name
- NCT00686998
- Testing
- AZD2624, Olanzapine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents.
- Trial name
- NCT00051298
- Testing
- Olanzapine
- Where
- 25 sites in United States, Russia
- Volunteers
- 107 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Key objectives of this clinical study are to: Determine how well intramuscular (IM) olanzapine depot works compared to placebo Evaluate the safety and tolerability of IM olanzapine depot compared to placebo Evaluate different…
- Trial name
- NCT00088478
- Testing
- Intramuscular Olanzapine Depot
- Where
- 37 sites in United States, Croatia and 1 more
- Volunteers
- 402 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156117
- Testing
- asenapine, olanzapine
- Volunteers
- 417 people
- Sponsor
- Organon and Co
Schizophrenia
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the…
- Trial name
- NCT00073164
- Testing
- Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
- Where
- 35 sites in United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company